Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells | Zendy

Diala Fare Dahabreh | Zendy; Jheem D. Medh | Zendy

Open Access

Activation of peroxisome proliferator activated receptor-gamma results in an atheroprotective apolipoprotein profile in HepG2 cells

Author(s) -

Diala Fare Dahabreh,

Jheem D. Medh

Publication year - 2012

Publication title -

advances in biological chemistry

Language(s) - English

Resource type - Journals

eISSN - 2162-2191

pISSN - 2162-2183

DOI - 10.4236/abc.2012.23026

Subject(s) - ciglitazone , endocrinology , medicine , apolipoprotein b , liver x receptor , ldl receptor , apolipoprotein e , receptor , peroxisome proliferator activated receptor , chemistry , cholesterol , biology , nuclear receptor , transcription factor , lipoprotein , biochemistry , disease , gene

Insulin resistance is linked to dyslipidemia, characterized by a decrease in high density lipoproteins and an increase in low density lipoproteins. Thiazolidinediones (TZDs) are insulin-sensitizing agents used to improve glycemic control in patients with type 2 diabetes. Recently, the safety of certain TZD regimens has been questioned because of associated adverse effects on the plasma lipid profile. We examined the effect of a TZD, Ciglitazone, on apolipoprotein synthesis and secretion in human liver HepG2 cells.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research